Company intelligence / Profile preview

Precision Biosensor

Daejeon/Yuseong-gu, Daejeon Metropolitan City, South Korea

Ownership: Private
Development stage: Commercial

Overview

Precision Biosensor commercializes point-of-care diagnostic devices using time-resolved fluorescence technology. Their Exdia TRF system provides rapid biomarker-based testing comparable to central laboratory analyzers. The company has established partnerships to expand its market reach and continues to develop next-generation molecular diagnostic platforms. (No drug or therapeutic clinical results as the focus is on diagnostics.)

Therapeutic areas: Other
Modalities: DeviceDiagnostic platform (Immuno-diagnosis, Clinical chemistry diagnosis)Molecular diagnostic platform (in development)
Industry: Protein Biomarker Diagnostics

Partnerships

NIPRO Corporation of Japan – partnership to expand clinical diagnostics market

Beyond the preview

Go deeper on Precision Biosensor.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Precision Biosensor.

Explore the full profile